Shareholders appeared to be happy with Harmony Biosciences Holdings, Inc.'s ( NASDAQ:HRMY ) solid earnings report ...

Looking for a stock that has been consistently beating earnings estimates and might be well positioned to keep the streak ...

Harmony Biosciences Holdings Inc (HRMY) reports a 20% increase in net product revenue and outlines strategic initiatives for ...

Harmony Biosciences Holdings, Inc.’s HRMY share price has surged by 7.38%, which has investors questioning if this is right ...

HRMY also plans to start a late-stage study on ZYN-002 in 22q11.2 deletion syndrome (22q) later this year. However, Harmony Biosciences is not devoid of pipeline/regulatory setbacks.

Benzinga tracks 150 analyst firms and reports on their stock expectations. Analysts typically arrive at their conclusions by ...

Harmony Biosciences has received a total of 12 ratings from analysts, with the consensus rating as Buy. With an average ...

We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...

$HRMY insiders have traded $HRMY stock on the open market 15 times in the past 6 months. Of those trades, 0 have been purchases and 15 have been sales. Here’s a ...

BofA lowered the firm’s price target on Harmony Biosciences (HRMY) to $32 from $33 and keeps an Underperform rating on the shares. The firm, in its preview of Q1 EPS updates for its commercial ...

Harmony Biosciences Holdings, Inc. (HRMY), which belongs to the Zacks Medical - Biomedical and Genetics industry, could be a great candidate to consider. This company has an established record of ...